Analysts Set Indivior PLC (NASDAQ:INDV) PT at $34.57

Shares of Indivior PLC (NASDAQ:INDV) have earned an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $34.5714.

A number of equities analysts have weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 target price (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Craig Hallum reissued a “buy” rating and issued a $41.00 target price on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $40.00 price target on Indivior in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st.

Indivior Stock Down 1.0%

INDV opened at $32.54 on Tuesday. Indivior has a 52 week low of $7.62 and a 52 week high of $38.00. The stock has a market cap of $4.07 billion, a PE ratio of 35.37 and a beta of 0.75. The business has a 50 day moving average of $34.34 and a 200-day moving average of $26.64.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.38 by $0.34. The business had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. Equities analysts anticipate that Indivior will post 1.22 EPS for the current year.

Insider Buying and Selling

In other Indivior news, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director directly owned 1,963 shares of the company’s stock, valued at $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David E. Wheadon purchased 1,771 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This represents a 14.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 4,871 shares of company stock worth $172,385 over the last 90 days.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC purchased a new position in shares of Indivior during the third quarter valued at approximately $25,000. Quarry LP purchased a new position in shares of Indivior in the 3rd quarter worth $26,000. Raymond James Financial Inc. bought a new stake in shares of Indivior in the second quarter worth $26,000. GAMMA Investing LLC increased its position in Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after acquiring an additional 1,013 shares during the last quarter. Finally, Plato Investment Management Ltd bought a new position in Indivior in the third quarter valued at about $52,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.